688276 百克生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.363-6.5095.63513.2195.204
总资产报酬率 ROA (%)-1.022-5.1124.52810.7404.293
投入资产回报率 ROIC (%)-1.240-6.2135.54813.1645.189

边际利润分析
销售毛利率 (%)78.41673.43585.42290.23387.193
营业利润率 (%)-21.198-54.92320.98230.65117.445
息税前利润/营业总收入 (%)-20.469-54.71620.50330.22516.574
净利润/营业总收入 (%)-17.109-43.39718.88327.45716.943

收益指标分析
经营活动净收益/利润总额(%)69.13172.837117.164113.717128.993
价值变动净收益/利润总额(%)31.96510.369-0.1720.1220.156
营业外收支净额/利润总额(%)0.002-0.127-0.8270.7925.452

偿债能力分析
流动比率 (X)1.2471.2882.1422.2122.872
速动比率 (X)0.9731.0831.9562.0162.603
资产负债率 (%)26.05024.02118.96520.33016.902
带息债务/全部投入资本 (%)10.0455.5442.2230.2700.076
股东权益/带息债务 (%)883.9651,682.3884,388.11836,887.943130,705.826
股东权益/负债合计 (%)283.874316.307427.278391.895491.638
利息保障倍数 (X)-28.074-397.447-66.861-45.043-8.828

营运能力分析
应收账款周转天数 (天)521.421696.855434.859249.781291.029
存货周转天数 (天)773.058444.951371.489395.045568.563